dr. mcdermott on long-term benefit with nivolumab in rcc
Published 8 years ago • 340 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
4:05
long-term rcc data with nivolumab
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
4:43
nivolumab in renal cell carcinoma
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc